Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded...
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
FOR FURTHER INFORMATION CONTACT:
Licensing information may be obtained by emailing the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development, 31 Center Drive, Room 4A25, MSC2479, Bethesda, MD 20892-2479;
NHLBI_TechTransfer@mail.nih.gov.
A signed Confidential Disclosure Agreement may be required to receive any unpublished information.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Hematopoietic Stem Cell and Progenitor Cell Transplantation Therapy Technology
Available for licensing and commercial development are patent rights covering recombinant bivalent (bi) single-chain variable fragment (scFV) minibody targeting the cMPL receptor on HSPCs, fused with diphtheria toxin (DT) truncated at residue 390 (DT390-biscFV(cMPL)) that can be used to deplete HSPCs with increased safety in patients undergoing HSPC transplantation. Patient conditioning is a critical initial step in hematopoietic stem and progenitor cell (HSPC) transplantation procedures, especially for leukemia patients, that enables marrow engraftment of infused cells. Conditioning regimens have traditionally been achieved by delivering cytotoxic doses of chemotherapeutic agents and radiation. However, these regimens are associated with significant morbidity and mortality and cannot be used safely in elderly or subjects with comorbidities.
Potential Commercial Applications:
Use as a novel conditioning regimen with increased safety for patients undergoing transplantation.
Investigational tool to study hematopoietic stem and progenitor cell (HSPC) biology and improve gene therapy and cell therapy.
Competitive Advantages:
( printed page 60383)
transplantation efficacy.
Limits chemotherapeutic cytotoxicity.
Better penetrants into deep tissue, such as bone marrow niche.
Short half-life allowing rapid clearance before cell re-infusion.
More efficiently dimerizes cMPL receptor than the whole IgG.
Development Stage:
Preclinical.
In vivo data available (animal).
Related Publications:
Araki D, Hong SG, Linde N, Fisk B, Redekar N, Salisbury-Ruf C, Krouse A, Engels T, Golomb J, Dagur P, Panicker SR, Kanthi Y, Magnani DM, Wang Z, Larochelle A. cMPL-based purification and depletion of human hematopoietic stem cells: implications for pretransplant conditioning. Blood. 2025 Jun 19;145(25):2978-2991. doi:10.1182/blood.2024024636. PMID: 40009502; PMCID: PMC12226764.
U.S. Provisional Application No. 63/251,883 filed October 4, 2022.
PCT Application No. PCT/US22/77326 filed September 30, 2022.
U.S. Application No. 18/688,899 filed March 4, 2024.
European Patent Application No. 22813001.9 filed March 8, 2024.
Israel Patent Application No. 311590 filed March 19, 2024.
China Patent Application No. 202280065162.6 filed March 26, 2024.
Collaborative Research Opportunity:
The National Heart, Lung, and Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Dr. Vincent Kolesnitchenko, 301-594-4115 or
vk5q@nih.gov
and reference E-188-2021-0.
Licensing Contact:
Vincent Kolesnitchenko, Ph.D.; 301-594-4115;
vk5q@nih.gov.
“This Notice is in accordance with 37 CFR 404.4 Authority to grant licenses.”
Dated: September 21, 2026.
Vincent A. Kolesnitchenko,
Senior Technology Transfer Manager, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development.
37 CFR 404.4